{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:24:27Z","timestamp":1790720667794,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":308,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1002\/rth2.12679","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T08:13:12Z","timestamp":1647418392000},"page":"e12679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model"],"prefix":"10.1016","volume":"6","author":[{"given":"Debra D.","family":"Pittman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Rakhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl R.","family":"Bowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Jasuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12679_bb0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1002\/rth2.12679_bb0015","first-page":"178","article-title":"The modern treatment of haemophilia: a narrative review","volume":"11","author":"Franchini","year":"2013","journal-title":"Blood Transfus"},{"key":"10.1002\/rth2.12679_bb0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MOH.0000000000000074","article-title":"Global assays of hemostasis","volume":"21","author":"Brummel\u2010Ziedins","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1002\/rth2.12679_bb0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12679_bb0030","unstructured":"World Federation of Hemophilia. World Federation of Hemophilia report on the annual global survey 2010. 2011. Available at: http:\/\/www1.wfh.org\/publications\/files\/pdf\u20101427.pdf Accessed: Apr 30, 2021."},{"key":"10.1002\/rth2.12679_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1002\/rth2.12679_bb0040","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0049-3848(16)30359-0","article-title":"Targeting TFPI for hemophilia treatment","volume":"141","author":"Peterson","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12679_bb0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2741\/3926","article-title":"Tissue factor pathway inhibitor: structure\u2010function","volume":"17","author":"Broze","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1002\/rth2.12679_bb0050","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1111\/jth.12897","article-title":"New insights into the biology of tissue factor pathway inhibitor","volume":"13","author":"Maroney","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12679_bb0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/338518a0","article-title":"Functional significance of the Kunitz\u2010type inhibitory domains of lipoprotein\u2010associated coagulation inhibitor","volume":"338","author":"Girard","year":"1989","journal-title":"Nature"},{"key":"10.1002\/rth2.12679_bb0060","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1074\/jbc.273.8.4378","article-title":"Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor","volume":"273","author":"Baugh","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1002\/rth2.12679_bb0065","unstructured":"Apgar J, Parng C, Benard S, Juo S, Tam M, Tu C, Rakhe S, Jin M, Svenson K, Murphy JE, Stahl M & Pittman DD X\u2010ray crystallography and hemostatic activities of a neutralizing anti\u2010TFPI antibody, marstacimab [poster]. Presented at: Annual Congress of the International Society on Thrombosis and Haemostasis; July 12\u201014, 2020."},{"issue":"suppl 1","key":"10.1002\/rth2.12679_bb0070","first-page":"PB0240","article-title":"X\u2010ray crystallography and hemostatic activities of a neutralizing anti\u2010TFPI antibody, marstacimab [abstract]","volume":"4","author":"Apgar","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12679_bb0075","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first\u2010in\u2010human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF\u201006741086, an anti\u2010tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12679_bb0080","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12679_bb0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"Patel\u2010Hett","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/rth2.12679_bb0090","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2006-07-037283","article-title":"Active tissue factor pathway inhibitor is expressed on the surface of coated platelets","volume":"109","author":"Maroney","year":"2007","journal-title":"Blood"},{"key":"10.1002\/rth2.12679_bb0095","doi-asserted-by":"crossref","first-page":"670526","DOI":"10.3389\/fmed.2021.670526","article-title":"Progress in the development of anti\u2010tissue factor pathway inhibitors for haemophilia management","volume":"8","author":"Mahlangu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1002\/rth2.12679_bb0100","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/hae.12873","article-title":"Pro\u2010 and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(\u00ae) in prophylactic therapy","volume":"22","author":"Varadi","year":"2016","journal-title":"Haemophilia"},{"key":"10.1002\/rth2.12679_bb0105","unstructured":"FEIBA [package insert]. Lexington, MA: Baxalta US Inc., 2018."},{"key":"10.1002\/rth2.12679_bb0110","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1182\/blood.V128.22.2566.2566","article-title":"An antibody to tissue factor pathway inhibitor (PF\u201006741086) in combination with recombinant factor VIIa increases hemostasis in hemophilia plasma without excessive thrombin generation [abstract]","volume":"128","author":"Rakhe","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12679_bb0115","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.xphs.2018.03.010","article-title":"Translational pharmacokinetic\/pharmacodynamic characterization and target\u2010mediated drug disposition modeling of an anti\u2010tissue factor pathway inhibitor antibody, PF\u201006741086","volume":"107","author":"Parng","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1002\/rth2.12679_bb0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1002\/rth2.12679_bb0125","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V72.6.2020.2020","article-title":"Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor","volume":"72","author":"Novotny","year":"1988","journal-title":"Blood"},{"key":"10.1002\/rth2.12679_bb0130","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nbt.1995","article-title":"A zymogen\u2010like factor Xa variant corrects the coagulation defect in hemophilia","volume":"29","author":"Ivanciu","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1002\/rth2.12679_bb0135","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1182\/blood.V128.22.3761.3761","article-title":"An antibody to tissue factor pathway inhibitor (TFPI) restores hemostasis after the onset of bleeding in hemophilic a mouse injury models [abstract]","volume":"128","author":"Jasuja","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12679_bb0140","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1538-7836.2009.03532.x","article-title":"Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice","volume":"7","author":"Holmberg","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12679_bb0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12679_bb0150","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/MBC.0b013e3282e7febb","article-title":"Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma","volume":"18","author":"Scharling","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1002\/rth2.12679_bb0155","unstructured":"FEIBA NF [product monograph]. Toronto, ON, Canada: Shire Pharma Canada, 2018."},{"issue":"suppl 2","key":"10.1002\/rth2.12679_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"Turecek","year":"2004","journal-title":"Haemophilia"},{"issue":"11","key":"10.1002\/rth2.12679_bb0165","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/jth.14288","article-title":"Re\u2010evaluation of Mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology","volume":"16","author":"Girard","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12679_bb0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12959-015-0038-0","article-title":"Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk","volume":"13","author":"Lipets","year":"2015","journal-title":"Thrombosis J"},{"key":"10.1002\/rth2.12679_bb0175","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"suppl 4","key":"10.1002\/rth2.12679_bb0180","first-page":"154","article-title":"Studies of Marstacimab, an anti\u2010tissue factor pathway (TFPI) inhibitor, in combination with factor replacement or bypassing agents [abstract F\u2010FP\u2010LBA\u20104.1]","volume":"26","author":"Peraza","year":"2020","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12679","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12679","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922011700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922011700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:25:01Z","timestamp":1762863901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922011700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2475037922011700"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12679","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}],"article-number":"e12679"}}